Table 1.

Mapping interactions between calnexin, calreticulin, ERp57, and PDI using MYTHS

	CNX H21P482	ERp57 A24-L505	PDI D18-L508	ERp57 K362R	ERp57 F386S	ERp57 W405R	ERp57 F476S	pLJ96	GST
ERp57 A24-L505	+++	−	+	−	−	−	−	−	+++
CNX H21−P482	−	+++	−	+++	+++	+++	+++	−	+++
CNX P270−F415 (11112222)	−	+++	−	+++	+++	+++	+++	−	+++
CNX D289−N393 (111222)	−	+++	−	+++	+++	+++	+++	−	+++
CNX P310−P378 (1122)	−	+++	−	+++	+++	+++	+++	−	+++
CRT E18-L417	−	+++	−	+++	+++	+++	+++	−	+++
CRT D201-A307 (111222)	−	+++	−	+++	+++	+++	+++	−	+++
CRT A223-P283 (1122)	−	+++	−	+++	+++	+++	+++	−	+++
PDI D18-L508	−	+	−	n/a	n/a	n/a	n/a	−	+++
CNX2pmA	−	+	−	+++	+++	+++	+++	−	+++
CNX6pmA	−	−	−	−	−	−	−	−	+++
pLJ89	−	−	−	−	−	−	−	−	+++
GST	+++	+++	+++	+++	+++	+++	+++	+++	+++
Results of using several calnexin and calreticulin P-domain constructs to map their interactions with ERp57. CNX and CRT deletion mutants are indicated, with the number of P-domain repeat motifs indicated in parenthesis. Specific point mutations in calnexin confirm acidic residues necessary for interaction. Error-prone PCR identifies point mutations in ERp57 that complement the mutated calnexin P-domain. The nature of each mutant fusion protein is described in the text. Plus symbols indicate the presence and strength of an interaction (‘+++' strongest to ‘+' weakest), and ‘−' indicates no interaction detected. ‘n/a' indicates data not available.